-+ 0.00%
-+ 0.00%
-+ 0.00%

60 Degrees Pharmaceuticals Presents Tafenoquine Development Update for Babesiosis

PUBT·10/23/2026 20:54:11
Listen to the news
60 Degrees Pharmaceuticals Presents Tafenoquine Development Update for Babesiosis
  • 60 Degrees Pharmaceuticals targets a potential supplemental new drug application for tafenoquine in babesiosis in 2027, seeking national-priority review.
  • The randomized hospital study enrolled 30 patients; blinded follow-up ends in early January 2027, with unblinding to follow.
  • Expanded-access treatment achieved confirmed post-treatment molecular clearance in the first three patients.
  • Published cases showed responses in six of seven patients receiving tafenoquine for at least eight weeks with concomitant atovaquone.
  • Chronic-study recruitment remains slow; none of nine screened patients tested positive for B. microti by nucleic acid testing.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. 60 Degrees Pharmaceuticals Inc. published the original content used to generate this news brief on October 24, 2026, and is solely responsible for the information contained therein.